BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23428543)

  • 1. Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins.
    Sumbria RK; Boado RJ; Pardridge WM
    Brain Res; 2013 Apr; 1507():91-6. PubMed ID: 23428543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein.
    Sumbria RK; Boado RJ; Pardridge WM
    J Cereb Blood Flow Metab; 2012 Oct; 32(10):1933-8. PubMed ID: 22714051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse.
    Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Drug Metab Dispos; 2010 Apr; 38(4):566-72. PubMed ID: 20075191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein.
    Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    Brain Res; 2011 Jan; 1369():203-7. PubMed ID: 21047502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain-penetrating tumor necrosis factor decoy receptor in the mouse.
    Zhou QH; Boado RJ; Hui EK; Lu JZ; Pardridge WM
    Drug Metab Dispos; 2011 Jan; 39(1):71-6. PubMed ID: 20884844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.
    Zhou QH; Sumbria R; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    J Pharmacol Exp Ther; 2011 Nov; 339(2):618-23. PubMed ID: 21831964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier.
    Fu A; Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    Brain Res; 2010 Sep; 1352():208-13. PubMed ID: 20599807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice.
    Sumbria RK; Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    Mol Pharm; 2013 Apr; 10(4):1425-31. PubMed ID: 23410508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
    Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
    Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein.
    Zhou QH; Boado RJ; Hui EK; Lu JZ; Pardridge WM
    Drug Metab Dispos; 2011 Jul; 39(7):1149-54. PubMed ID: 21502195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier.
    Boado RJ; Zhang Y; Zhang Y; Wang Y; Pardridge WM
    Biotechnol Bioeng; 2008 Jun; 100(2):387-96. PubMed ID: 18080333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
    Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
    Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
    Pardridge WM; Boado RJ
    Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse.
    Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    Brain Res; 2011 Mar; 1382():315-20. PubMed ID: 21276430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse.
    Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Drug Metab Dispos; 2012 Feb; 40(2):329-35. PubMed ID: 22065691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein.
    Zhou QH; Lu JZ; Hui EK; Boado RJ; Pardridge WM
    Bioconjug Chem; 2011 Aug; 22(8):1611-8. PubMed ID: 21707084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey.
    Boado RJ; Pardridge WM
    Drug Metab Dispos; 2009 Dec; 37(12):2299-304. PubMed ID: 19741036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.
    Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
    J Biotechnol; 2010 Mar; 146(1-2):84-91. PubMed ID: 20100527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein.
    Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    Brain Res; 2010 Nov; 1360():193-7. PubMed ID: 20833153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.